A phase II study of Erlotinib as 2nd-line treatment for patients with StageIIIB/IV non-small cell lung cancer
Phase 2
- Conditions
- non-small cell lung cancer
- Registration Number
- JPRN-UMIN000006078
- Lead Sponsor
- Yamagata University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 31
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients with active lung disease such as interstitial pneumonia, pneumoconiosis, active radiation pneumonitis,or drug-induced pneumonitis 2)Patients with active severe infections 3)Impossible cases with oral administration 4)Patients with active opthalmological disease 5)Pregnancy or lactation 6)Patients with active concomitant malignancy 7)Patients with uncontrollable diabetes mellitus 8)Patients with uncontrollable complications 9)Inappropriate patients for this study judged by the physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method